Sermorelin Reconstitution Calculator

Yes, but only historically for pediatric growth hormone deficiency/short stature indications; it is not an FDA-approved anti-aging, fat-loss, muscle-building, or sports-medicine drug. Current adult wellness use is off-label or compounded-market use rather than an approved modern indication. (human clinical trial/review)

Sermorelin is a growth hormone-releasing hormone (GHRH 1-29) analog that stimulates pituitary GHRH receptors and increases endogenous pulsatile growth hormone release, which then raises IGF-1 if the pituitary-somatic axis is intact. Because it relies on your own pituitary reserve, it tends to work better in functional GH insufficiency than in severe pituitary failure, and it preserves physiologic pulsatility better than exogenous GH. (human clinical trial/mechanistic)

Published adult GHRH studies used nightly injections rather than daytime boluses, supporting bedtime timing to align with physiologic nocturnal GH secretion. In older adults, single nightly GHRH 1-29 injections showed endocrine effects, and longer-term nightly GHRH analog administration increased IGF-1 and altered body composition modestly. (human clinical trial)

Practical dosing used in clinics is usually:

Common body-weight heuristic: ~1-3 mcg/kg nightly, usually capped around 300-500 mcg/night in practice (community protocol). Response is usually tracked with IGF-1, fasting glucose, and symptom change rather than dose alone. (practitioner consensus)

Yes. Sermorelin is an injectable peptide and, like most peptides, has poor oral stability and low oral bioavailability because of gastrointestinal degradation. Subcutaneous injection is the standard practical route; it is the route generally used for peptide therapies of this class and the route assumed in real-world protocols. (review/mechanistic)

Endocrine effects on GH occur acutely after injection, but body-composition or recovery changes are slower. In adults, IGF-1 changes can appear within days to weeks, while any visible changes in sleep, recovery, waist circumference, or lean mass usually require 6-12 weeks, and effects are modest rather than dramatic. (human clinical trial/review)

Longer use is typically done in blocks of 3-6 months with lab reassessment every 6-8 weeks (practitioner consensus). Continuous indefinite use is not evidence-based; long-term adult data are limited, and benefit depends on preserved pituitary responsiveness. (review)

Sermorelin is shorter-acting and less potent than tesamorelin or long-acting CJC-1295, but it is closer to physiologic GHRH signaling. Tesamorelin has stronger human outcome data, especially for reducing visceral adipose tissue in HIV-associated lipodystrophy, while CJC-1295 has a much longer half-life because of DAC modification. (human clinical trial/review)

Compared with exogenous GH, Sermorelin is generally milder, depends on an intact pituitary, and is less likely to fully override physiologic feedback. The tradeoff is smaller and less predictable effects on IGF-1, body composition, and performance. (review/human clinical trial)

Reported adverse effects are generally those expected from GH-axis stimulation: flushing, headache, nausea, dizziness, and injection-site irritation; edema, arthralgia, or carpal-tunnel-like symptoms can occur if IGF-1 rises substantially. Because it stimulates endogenous GH/IGF-1 signaling, monitoring glucose tolerance and IGF-1 is reasonable, especially in people with insulin resistance. (human clinical trial/review)

If someone has active malignancy, proliferative retinopathy, uncontrolled diabetes, or untreated intracranial pathology, caution is warranted because GH/IGF-1 signaling is trophic and metabolically active. Evidence for these concerns is mostly mechanistic and class-based rather than Sermorelin-specific harm data. (review/mechanistic)

Women can use it; older-adult studies included men and women and showed endocrine/metabolic effects with chronic GHRH analog administration. There is no meaningful evidence base supporting use during pregnancy or breastfeeding, so avoidance is standard. (human clinical trial)

For fertility-focused users, Sermorelin is not a fertility drug. If used in women, monitoring should focus on IGF-1, fasting glucose, edema, headaches, and any cycle changes (practitioner consensus).

Possibly, but expectations should stay modest. Human GH-axis secretagogue data show increases in GH/IGF-1 and small improvements in body composition, especially in older adults with reduced GH secretion, but they do not reliably produce bodybuilding-level changes in lean mass or rapid fat loss. (human clinical trial/review)

It is better thought of as a mild GH-axis support drug than a direct anabolic. For visceral-fat reduction, tesamorelin has stronger evidence; for large body-composition effects, Sermorelin is weaker. (review/human clinical trial)

As a peptide, Sermorelin is degradation-prone and should generally be kept refrigerated after reconstitution to preserve stability; peptide instability is a class property and improper handling accelerates degradation. Keep the vial protected from heat, avoid repeated room-temperature exposure, and use bacteriostatic diluent if the dispensing pharmacy instructs it. (mechanistic/review)

For travel, use an insulated medication case with a cold pack and avoid freezing the vial (practitioner consensus). Also note that GHRH analogs including sermorelin are prohibited in sport under anti-doping rules, and sensitive urine assays can detect sermorelin and metabolites at very low concentrations. (analytical/antidoping)